Lyell Immunopharma, Inc. (LYEL)
US — Healthcare Sector
Automate Your Wheel Strategy on LYEL
With Tiblio's Option Bot, you can configure your own wheel strategy including LYEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LYEL
- Rev/Share 0.0022
- Book/Share 18.0163
- PB 1.4226
- Debt/Equity 0.1346
- CurrentRatio 10.2955
- ROIC -0.9118
- MktCap 543810599.0
- FreeCF/Share -9.0615
- PFCF -3.2852
- PE -1.4377
- Debt/Assets 0.1086
- DivYield 0
- ROE -0.9668
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | LYEL | H.C. Wainwright | Neutral | Buy | -- | $45 | Dec. 9, 2025 |
News
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data
LYEL
Published: December 24, 2025 by: Seeking Alpha
Sentiment: Positive
Published: December 24, 2025 by: Seeking Alpha
Sentiment: Positive
Lyell Immunopharma (LYEL) has surged 191% YTD, driven by strong momentum and promising CAR T-cell therapy pipeline candidates LYL314 and LYL273. LYL314 achieved a 93% overall response and 76% complete response rate in heavily pre-treated LBCL, positioning LYEL as a differentiated player in CAR T therapies. LYEL maintains a $320 million cash position, funding operations into 2027, with pivotal LYL314 trial data and a BLA submission targeted for 2027.
Read More
About Lyell Immunopharma, Inc. (LYEL)
- IPO Date 2021-06-17
- Website https://www.lyell.com
- Industry Biotechnology
- CEO Lynn Seely
- Employees 300
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.